Improve Your Prognosis Get a free mesothelioma guide

Peritoneal Mesothelioma

Peritoneal mesothelioma is a cancer that develops in the lining of the abdomen. Asbestos exposure is the primary cause. About half of patients who qualify for surgery with heated chemotherapy live longer than five years.

Peritoneal mesothelioma is the second-most common form of mesothelioma. It accounts for approximately 10 to 15 percent of all cases.

This cancer is caused by exposure to asbestos. People who worked with asbestos products throughout their career are most at risk.

The latency period associated with peritoneal mesothelioma is shorter than for the pleural form of the disease. Peritoneal mesothelioma latency is 20-30 years, compared to 30-40 years for pleural mesothelioma.

The prognosis for most patients is poor. Most patients are diagnosed with the diffuse form of the disease, which is very aggressive. The median survival for untreated patients is around six months.

However, selected patients can be treated with surgery and heated chemotherapy. The median survival of such patients ranges between 30 and 92 months.

Causes

Exposure to asbestos is the primary cause of peritoneal mesothelioma. Asbestos is a mineral that was used in industrial, commercial and domestic products.

Most people who get sick from exposure worked with asbestos products for many years.

Symptoms

Ascites, a buildup of fluid in the peritoneal lining, is present in 90 percent of peritoneal patients.

Diagnosis

Abdominal pain, bloating and changes in bowel habits are the most common symptoms that cause patients to visit the doctor.

A variety of tests are used to diagnose the cancer including imaging scans, ascites fluid tests and tumor biopsies. An official diagnosis usually requires a laparoscopic biopsy.

Biopsies provide tumor samples that are examined with a microscope to identify the exact type of cancer cells present. More than 80 percent of peritoneal tumors are made up of epithelial cells. These cells respond better to treatment than the other cancer cell types such as sarcomatoid and biphasic cells.

Staging

Unlike pleural mesothelioma, there is no official staging system for the peritoneal form of the disease.

Doctors have identified three stages based on studies of peritoneal patients undergoing surgery. A fourth stage hasn’t been clearly identified, but it is generally accepted that the fourth stage involves local spread of tumors throughout the abdomen.

Stage 1: Cancer cells remain within the peritoneal lining. Lymph nodes do not contain cancer cells.

Stage 2: Cancer cells have grown in number, but haven’t spread far or entered lymph nodes.

Stage 3: Cancer cells are more prevalent and have spread throughout the abdominal lining and into lymph nodes.


Need Help Finding a Specialist?

Call Us Now for Free Assistance (877) 546-0696


Treatment

Treatment for peritoneal mesothelioma involves surgery and chemotherapy.

Surgery is more effective for peritoneal mesothelioma than for the pleural form of the disease. In practice, this means that peritoneal patients who undergo surgery tend to live longer than pleural patients who undergo surgery.

Conversely, radiation therapy is less effective. Radiation is rarely used on peritoneal patients.

Surgery

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, commonly called HIPEC or heated chemotherapy, is the most effective treatment for this cancer. The median survival after treatment ranges between 30 and 92 months.

A minor surgical procedure, called paracentesis, is used on patients with ascites. This procedure is often used to relieve symptoms of abdominal swelling and pain associated with fluid buildup.

Chemotherapy

The most effective chemotherapy drugs for peritoneal mesothelioma include Alimta (pemetrexed), cisplatin, carboplatin and gemcitabine.

Experimental Therapies

Experimental therapies are under investigation in clinical trials. Examples include immunotherapy and gene therapy.

Complementary Therapies

A number of peritoneal patients try complementary therapies to ease cancer symptoms and reduce treatment side effects. Examples include nutritional therapy, acupuncture, tai chi and relaxation therapies.

Doctors and Cancer Centers

Paul H. Sugarbaker, M.D.

Director of Surgical Oncology at Washington Cancer Center

Dr. Sugarbaker is the nation’s leading expert on peritoneal mesothelioma. He pioneered life-saving surgical techniques for the cancer, including the Sugarbaker Procedure, also known as cytoreductive surgery with heated chemotherapy.

W. Charles Conway, M.D.

Director of Surgical Oncology at Ridley-Tree Cancer Center

Dr. Conway specializes in surgery for peritoneal mesothelioma. He has had great success treating peritoneal patients with cytoreductive surgery and heated chemotherapy. Conway also specializes in robotic surgery.

J.F. Pingpank, Jr., M.D.

Associate Professor of Surgery at UPMC Hillman Cancer Center

Dr. Pingpank is a peritoneal mesothelioma surgical expert. He is an advocate of regional treatment for peritoneal mesothelioma including hyperthermic intraperitoneal chemotherapy, which applies chemotherapy only within the abdominal region.

Prognosis

The prognosis for the majority of peritoneal mesothelioma patients is poor. Average survival is around six months in untreated patients.

Selected patients can be treated with cytoreductive surgery and heated chemotherapy. Survival among these patients is between 30 and 92 months.

Systemic chemotherapy is the next-best option for patients who are diagnosed too late for surgery.

A 2017 study of peritoneal patients reported the outcomes of chemotherapy with cisplatin and Alimta delivered systemically (throughout the body). About 45.8 percent of participants responded to the drugs, and their tumors were controlled for an average of 11 months. Overall survival was 15.8 months.

However, patients in this study with a form of peritoneal mesothelioma known as “wet-type” had an average survival of 40.9 months. Numerous studies have reported longer survival among patients with this type of the disease regardless of the treatment they receive.

Untreated peritoneal mesothelioma is associated with an average survival of eight months.

A 2017 study that included 53 peritoneal mesothelioma patients reported that 21.5 percent of them received no cancer treatment. It also reported that 51.8 percent underwent at least one surgical procedure.

The best way for patients to improve their prognosis with peritoneal mesothelioma is to work with a specialist. Additionally, patients can consider clinical trials to access new treatment options.

Written By Vanessa Blanco
Medical Review By Dr. Susan E. Lawrence

Sources

  1. Pass, I., Vogelzang, N., & Carbone, M. (2005). Surgery, Hyperthermic Chemoperfusion, and Postoperative Chemotherapy: The National Cancer Institute and Washington Hosptial Center Experience. In Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. Springer: New York.
  2. Pass, I., Vogelzang, N., & Carbone, M. (2005). Clinical Presentation and Natural History of Mesothelioma: Abdominal. In Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. Springer: New York.
  3. Sugarbaker, P.H., & Chang, D. (2017). Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. International Journal of Hyperthermia, 33(5), 582-592. Retrieved from http://dx.doi.org/10.1080/02656736.2017.1291999
  4. Magge, D. et al. (2014). Malignant peritoneal mesothelioma: Prognostic factors and oncologic outcome analysis. Annals of Surgical Oncology, 21(4), 1159-1165. doi: 10.1245/s10434-013-3358-y.
  5. Kim, J., Bhagwandin, S., & Labow, D.M. (2017). Malignant peritoneal mesothelioma: A review. Ann Transl Med., 5(11), 236. doi: 10.21037/atm.2017.03.96
  6. Macuks, R. et al. (2011). Malignant intraperitoneal mesothelioma – Baskent University experience. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939100/
  7. Hotta, T. et al. (2004). Chemotherapy and serum hyaluronic acid levels in malignant peritoneal mesothelioma. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15239250/
  8. Fujimoto, E. et al. (2017). First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28594258
  9. Yan. T. et al. (2011, May 1). A Novel Tumor-Node-Metastasis (TNM) Staging System of Diffuse Malignant Peritoneal Mesothelioma Using Outcome Analysis of A Multi-Institutional Database. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/cncr.25640/pdf
  10. Enewold, L., Sharon, E. & Thomas, A. (2017, August 10). Patterns of Care and Survival Among Patients with Malignant Mesothelioma in the United States. Retrieved from http://www.lungcancerjournal.info/article/S0169-50021730448-8/abstract
  11. Boffetta, P. (2007). Epidemiology of peritoneal mesothelioma: a review. Ann Oncol., 18(6):985. Retrieved from https://academic.oup.com/annonc/article/18/6/985/241277

Do You or a Loved One Have Mesothelioma?
Get a Free Guide

Order Now